Author Archives:

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

Posted on by

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes




Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $2.5 billion aggregate principal amount (the “Offering”) of the following notes:


  • $500 million aggregate principal amount of its 4.200% senior notes due 2031 (the “2031 notes”) at the issue price of 99.874% of their principal amount;
  • $750 million aggregate principal amount of its 4.473% senior notes due 2032 (the “2032 notes”) at the issue price of 100.000% of their principal amount;
  • $750 million aggregate principal amount of its 4.794% senior notes due 2035 (the “2035 notes”) at the issue price of 100.000% of their principal amount; and
  • $500 million aggregate principal amount of its 4.894% senior notes due 2037 (the “2037 notes” and, together with the 2031 notes, the 2032 notes and the 2035 notes, the “notes”) at the issue price of 100.000% of their principal amount.

The Offering is expected to close on or about October 7, 2025, subject to the satisfaction of customary closing conditions. The notes will pay interest on a semi-annual basis.

Thermo Fisher intends to use the net proceeds from the sale of the notes for general corporate purposes, which may include the acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures or the repurchase of its outstanding equity securities or it may temporarily invest the net proceeds in short-term, liquid investments until they are used for their ultimate purpose.

The joint book-running managers for the Offering are J.P. Morgan Securities LLC, ING Financial Markets LLC, Mizuho Securities USA LLC and Scotia Capital (USA) Inc.

The Offering is being made pursuant to an effective registration statement on Form S-3ASR (File No. 333-285159) filed by Thermo Fisher with the U.S. Securities and Exchange Commission (the “SEC”) on February 24, 2025 and only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and an issuer free writing prospectus have been filed, and a prospectus supplement relating to the Offering will be filed, with the SEC, to which this communication relates. Prospective investors should read the issuer free writing prospectus, preliminary prospectus supplement and accompanying prospectus forming a part of that registration statement and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and the Offering. These documents are available at no charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, Thermo Fisher, the underwriters or any dealer participating in the Offering will arrange to send you the prospectus and the prospectus supplement if you request it by calling J.P. Morgan Securities LLC collect at 1-212-834-4533, ING Financial Markets LLC toll-free at 1-877-446-4930, Mizuho Securities USA LLC toll-free at 1-866-271-7403, or Scotia Capital (USA) Inc. toll-free at 1-800-372-3930.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the notes, nor shall there be any offer, solicitation or sale of the notes in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about timing and completion of the Offering and Thermo Fisher’s intended use of proceeds therefrom. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including risks and uncertainties relating to capital markets conditions and completion of the Offering. Additional important factors and information regarding Thermo Fisher’s business that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” section of the prospectus dated February 24, 2025 and the preliminary prospectus supplement dated September 30, 2025 related to the Offering and in Part 1, Item 1A. “Risk Factors” of Thermo Fisher’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and the other documents incorporated by reference into the prospectus and prospectus supplement, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if circumstances change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Contacts

Media Contact Information:

Sandy Pound

Thermo Fisher Scientific

Phone: 781-622-1223

E-mail: sandy.pound@thermofisher.com

Investor Contact Information:

Rafael Tejada

Thermo Fisher Scientific

Phone: 781-622-1356

E-mail: rafael.tejada@thermofisher.com

Toragen, Inc. Announces $12 Million Convertible Note Financing and Expansion of Board of Directors

Posted on by

Toragen, Inc. Announces $12 Million Convertible Note Financing and Expansion of Board of Directors




Toragen, Inc. Announces $12 Million Convertible Note Financing and Expansion of Board of Directors

SAN DIEGO–(BUSINESS WIRE)–Toragen, Inc., a clinical-stage biotechnology company developing a first-in-class, oral small molecule HPV E5 protein inhibitor targeting cancers caused by the human papillomavirus (“HPV”), today announced the successful completion of a $12 million convertible note financing.

The financing was led by Steven Lebow, who will join Toragen’s Board of Directors along with his designee, Dr. Scott Rasgon. GenHenn Capital also participated with a significant investment and will be represented on the Board by Bill Hagaman, COO of GenHenn Capital. In addition, Cathleen May, PhD, will assume the Board seat of the late Paul Engler, representing the Paul F. and Virginia J. Engler Foundation.

“This financing enables us to advance the next critical steps in developing TGN-S15, our lead candidate, and prepare for our upcoming clinical trial,” said Sandra Coufal, MD, CEO of Toragen. “We are grateful for the support of our investors and are excited to welcome four distinguished new members to our Board who bring deep expertise and commitment to our mission of developing an effective treatment for HPV-driven cancers.”

The majority of proceeds from this financing will support CMC and IND-enabling studies for TGN-S15.

About Steven E. Lebow

Steven Lebow is widely recognized in the investment banking community for his 21-year tenure as Managing Director at Donaldson, Lufkin & Jenrette (DLJ), where he led the Retail Investment Banking Group and advised clients across the U.S., Europe, and Latin America.

He has been an early investor in companies including Costco, Starbucks, PetSmart, Dick’s Sporting Goods, and Ulta Beauty, generating returns between 100x and 600x and helping drive their combined market capitalization above $600 billion. In recognition of his achievements, Steven was inducted into the DLJ “Hall of Fame” in 1995.

He later co-founded Global Retail Partners, a venture capital firm that became GRP Partners, and has continued to be a prominent figure in finance and investment. Steven earned his BA in Economics and Political Science, magna cum laude and Phi Beta Kappa, from UCLA and an MBA from the Wharton School at the University of Pennsylvania, where he was awarded the Exxon Fellowship.

About Toragen

Toragen is focused on targeting the root cause of HPV-induced cancers. The company has successfully completed a Phase 1 clinical trial in Stage 4 HPV+ head and neck cancer patients, meeting both primary endpoints of safety and maximum tolerated dose. The trial also demonstrated drug activity in 53% of patients treated. Learn more at www.toragen.com.

Contacts

Toragen, Inc.

Sandra Coufal, MD

Chief Executive Officer

scoufal@toragen.com

Stephenson Global Prize Awards $1 Million to Dr. Frank McCormick for Innovation in Pancreatic Cancer Research

Posted on by

Stephenson Global Prize Awards $1 Million to Dr. Frank McCormick for Innovation in Pancreatic Cancer Research




Stephenson Global Prize Awards $1 Million to Dr. Frank McCormick for Innovation in Pancreatic Cancer Research

Award Highlights Critical Role of Philanthropy Amid Federal Cancer Research Shortfalls

BOSTON–(BUSINESS WIRE)–The global cancer research community today celebrated a historic milestone, awarding the inaugural Stephenson Global Prize to Dr. Frank McCormick for his groundbreaking discoveries that have transformed the fight against pancreatic cancer.


Pancreatic cancer is the third leading cause of cancer-related death in the U.S. and carries the lowest five-year survival rate, just 13%. Despite its devastating toll, federal funding for pancreatic cancer research has long lagged behind other major cancers. Recent shortfalls and uncertainty in NIH funding have only heightened the urgent need for private philanthropy to fill this gap. The Stephenson Global Prize—presented with a $1 million unrestricted award—is designed to empower visionary researchers with the resources to accelerate discoveries that could change the trajectory of this deadly disease.

In honor of their beloved wife and mother, Toni Stephenson, A. Emmet Stephenson Jr. and Tessa Stephenson Brand made a $150 million philanthropic gift that established the Stephenson Global Prize and catalyzed the launch of the Stephenson Global Pancreatic Cancer Research Institute (SGPCRI).

“We created the Stephenson Global Prize because too many brilliant ideas in pancreatic cancer research never get the funding they need,” said A. Emmet Stephenson. “With federal resources stretched thin, philanthropy must step in to ensure that scientists like Dr. McCormick have the freedom to pursue breakthroughs without barriers.”

Tessa Stephenson Brand added, “Every day, families are touched by this devastating disease. By fueling innovative research, we can accelerate the breakthroughs that will save lives.”

Dr. McCormick, Professor at the UCSF Helen Diller Family Comprehensive Cancer Center, was honored for uncovering how mutations in the KRAS gene—present in more than 90% of pancreatic ductal adenocarcinomas—drive tumor growth. Once thought impossible to target, this discovery has paved the way for new therapies and brought renewed hope to patients and families worldwide.

“This recognition is deeply meaningful,” said Dr. McCormick. “Pancreatic cancer remains one of the most challenging diseases we face, and I’m honored to share this award with my lab as we continue exploring new ways to target KRAS and develop therapies that could change lives.”

The award was presented during the AACR Special Conference on Advances in Pancreatic Cancer Research in Boston, before an international audience of scientists, clinicians, and advocates united in the fight against one of the world’s deadliest cancers.

“By investing in early detection, prevention, treatment, translational research, and scientific discovery, the annual Stephenson Global Prize and Scholar Grants not only celebrate transformative achievements but also fuels hope and inspires perseverance, reminding researchers that breakthroughs are within reach,” said Jennifer Chun Kim, Executive Director of SGPCRI.

Beyond the Prize: A Comprehensive Strategy

In addition to the Stephenson Global Prize, SGPCRI is advancing a multi-pronged approach to accelerate progress against pancreatic cancer:

  • Stephenson Global Scholar Grants: Empowering investigators to pursue innovative ideas, these grants provide substantial funding to fuel transformative research. By cutting through bureaucracy and eliminating red tape, SGPCRI fosters true innovation and courageous risk-taking, accelerating discoveries with the potential to revolutionize treatment and detection while improving survival rates and patient outcomes. This year’s $5.3 million inaugural scholar grant recipients include:

    • Dr. Matthew Vander Heiden (MIT): Developing a multimodal platform that combines stool, blood, and CT imaging to detect pancreatic cancer before symptoms appear, leveraging changes in organ function as early warning signs.
    • Dr. Forest White and Dr. Tyler Jacks (MIT): Using mass spectrometry to identify new peptide antigens that emerge after KRAS inhibition, enabling vaccine and BiTE strategies that link targeted therapy with immunotherapy.
  • Annual Stephenson Pancreatic Cancer Symposium: Each year, SGPCRI hosts this premier gathering to honor Global Prize recipients, showcase breakthroughs achieved through the Scholar Grants, and unite the research community. The symposium serves as a vital platform for collaboration and momentum in the global fight against pancreatic cancer.

About the Stephenson Global Pancreatic Cancer Research Institute (SGPCRI)

The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) is dedicated to transforming the future of pancreatic cancer research through groundbreaking innovation, global collaboration, and strategic funding initiatives. Established through a transformative $150 million gift from philanthropists A. Emmet Stephenson Jr. and Tessa Stephenson Brand, SGPCRI is committed to advancing early detection, pioneering treatments, and high-impact research to improve patient outcomes. Working with leading scientists, clinicians, and institutions worldwide, SGPCRI fosters collaboration to accelerate breakthroughs in the fight against one of the world’s most challenging cancers. For more information, visit us on our website or follow us on LinkedIn and X.

Contacts

Media Contact:
Kria Sakakeeny, (401) 359-2219, kria@ekkopr.com

The Beauty Health Company Names Pedro Malha President and Chief Executive Officer

Posted on by

The Beauty Health Company Names Pedro Malha President and Chief Executive Officer




The Beauty Health Company Names Pedro Malha President and Chief Executive Officer

Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1

Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth

LONG BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) — The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced the appointment of Pedro Malha as President and Chief Executive Officer, effective October 1, 2025. He succeeds Marla Beck, who is stepping down as President and CEO effective September 30, 2025, and will remain in an advisory role.

Brent Saunders, Chairman of the Board, stated, “Pedro is an accomplished leader with broad industry experience at leading multinational companies in the healthcare and medical device sectors. His ability to navigate complex global markets and build collaborative, high-performing teams makes him the right person to lead BeautyHealth into its next chapter. We are also grateful for Marla’s strong leadership during a pivotal period of transformation, which has left BeautyHealth well positioned for sustainable and profitable growth.”

During her tenure, Ms. Beck guided BeautyHealth through a period of significant change, reigniting the Company’s science-backed innovation pipeline, streamlining and upgrading manufacturing, quality control, and operations, and refining the cost structure to strengthen margins and return the Company to profitability. She also reinforced Hydrafacial’s dual commitment to both providers and consumers, ensuring it remains the gold standard in performance skin health.

Ms. Beck said: “I am incredibly proud of what we have accomplished together to strengthen BeautyHealth’s foundation and future. With the right team and strategy in place, I believe now is the right time to welcome a new CEO to lead the Company into its next phase of growth. BeautyHealth has a robust pipeline of innovation and bold brand initiatives currently underway, and I look forward to watching the Company continue to thrive under Pedro’s leadership.”

Mr. Malha joins BeautyHealth following a distinguished global career spanning more than two decades across the healthcare and medical device industries. He most recently served as Worldwide Division President and Corporate Officer of Abbott Laboratories, where he led the neuromodulation business. Prior to that, he held senior leadership roles overseeing multiple global business units at Zimmer Biomet Holdings, Abbott, and Johnson & Johnson in Europe, where he consistently delivered growth and operational excellence. He holds an MBA from Boston University and a Bachelor of Science from Bentley University.

“I am honored to join BeautyHealth and lead this exceptional Company into the future,” stated Mr. Malha. “Hydrafacial is a category-defining brand with unmatched potential at the intersection of beauty and health. I look forward to working alongside the Board, the leadership team, and our global community of providers to shape the future of skin health through continued science-backed innovation and operational excellence, while accelerating profitable growth and creating lasting value for stakeholders around the world.”

About The Beauty Health Company

The Beauty Health Company (NASDAQ: SKIN) is a medtech meets beauty company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies, and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners, and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider/ and learn more at beautyhealth.com or LinkedIn.

Contacts: 
Hydrafacial Media Contact: press@beautyhealth.com
Investors: IR@beautyhealth.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6d01c322-0bb8-4a02-bb64-eba8c518ee54

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

Posted on by

Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares




Alpha Cognition Inc. Announces Proposed Public Offering of Common Shares

VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that it is proposing to offer and sell its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares, in an underwritten public offering. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to a number of additional common shares equal to 15% of the total number of common shares (and common shares underlying pre-funded warrants) sold in the proposed public offering, on the same terms and conditions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed public offering may be completed, or as to the actual size or terms of the proposed public offering. All securities to be sold in the proposed public offering will be offered by the Company.


The Company plans to allocate the net proceeds for the acceleration of commercial launch, with an emphasis on sales expansion, marketing investment, and enhancing payer coverage and reimbursement infrastructure. These investments are designed to maximize near-term adoption while laying the foundation for long-term revenue growth and a sustainable commercial presence in the Alzheimer’s treatment landscape.

Titan Partners Group, a division of American Capital Partners, is acting as sole bookrunner for this proposed public offering.

The proposed public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-289792) filed with the Securities and Exchange Commission (“SEC”) on August 22, 2025, and declared effective by the SEC on August 29, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed public offering, when available, may also be obtained by contacting Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, by phone at (929) 833-1246 or by email at prospectus@titanpartnersgrp.com.

This proposed public offering will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Alpha Cognition Inc.

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s Disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.

ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI.

Forward-looking Statements

This news release includes forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the completion, timing and size of the Company’s proposed public offering, the grant to the underwriter of an option to purchase additional securities, the satisfaction of customary closing conditions, and the intended use of proceeds therefrom. Except for statements of historical fact, any information contained in this news release may be a forward-looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company’s intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company’s filings with the SEC, including those risk factors under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and our periodic reports on Form 10-Q and Form 8-K filed with the SEC available at www.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.

Contacts

For further information:

Investor Relations

IR@alphacognition.com
https://www.alphacognition.com/

AB Science announces a slight delay in the publication of its 2025 half-year financial report

Posted on by

AB Science announces a slight delay in the publication of its 2025 half-year financial report




AB Science announces a slight delay in the publication of its 2025 half-year financial report

PRESS RELEASE

AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2025 HALF-YEAR FINANCIAL REPORT

THE COMPANY WILL PUBLISH ITS HALF-YEAR FINANCIAL REPORT FOR 2025 ON OCTOBER 10, 2025, AT THE LATEST

Paris, September 30 2025, 6.30pm CET

AB Science SA (Euronext – FR0010557264 – AB) today announced that it has postponed the publication of its financial report for the first half of 2025, initially scheduled for 30 September 2025, to give the auditors time to complete their audit work.

The Company will publish its financial report for the first half of 2025 on Friday 10 October 2025, at the latest.

About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment.

AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).

Further information is available on AB Science’s website: www.ab-science.com.

Forward-looking Statements – AB Science
This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.

These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents published by AB Science. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.

For additional information, please contact:

AB Science
Financial Communication & Media Relations
investors@ab-science.com

Attachment

IPSEN – Buy-back programme – Art 5 of MAR – Week 39 – 2025

Posted on by

IPSEN – Buy-back programme – Art 5 of MAR – Week 39 – 2025




IPSEN – Buy-back programme – Art 5 of MAR – Week 39 – 2025

Aggregated presentation by day and by market

Statement of transactions in own shares from September 22nd to September 26th 2025

             
Name of the issue Identity code of the issuer
(Legal Entity Identifier) 		Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code)
IPSEN 549300M6SGDPB4Z94P11 22/09/2025 FR0010259150 300 115,90 AQEU
IPSEN 549300M6SGDPB4Z94P11 22/09/2025 FR0010259150 600 116,30 CCXE
IPSEN 549300M6SGDPB4Z94P11 22/09/2025 FR0010259150 300 116,20 TQEX
IPSEN 549300M6SGDPB4Z94P11 22/09/2025 FR0010259150 3400 115,85629 XPAR
IPSEN 549300M6SGDPB4Z94P11 23/09/2025 FR0010259150 275 112,62727 AQEU
IPSEN 549300M6SGDPB4Z94P11 23/09/2025 FR0010259150 1167 113,15596 CCXE
IPSEN 549300M6SGDPB4Z94P11 23/09/2025 FR0010259150 235 112,64681 TQEX
IPSEN 549300M6SGDPB4Z94P11 23/09/2025 FR0010259150 2923 113,84872 XPAR
IPSEN 549300M6SGDPB4Z94P11 24/09/2025 FR0010259150 185 115,08649 AQEU
IPSEN 549300M6SGDPB4Z94P11 24/09/2025 FR0010259150 1013 114,95716 CCXE
IPSEN 549300M6SGDPB4Z94P11 24/09/2025 FR0010259150 148 114,99797 TQEX
IPSEN 549300M6SGDPB4Z94P11 24/09/2025 FR0010259150 3254 115,17560 XPAR
IPSEN 549300M6SGDPB4Z94P11 25/09/2025 FR0010259150 290 111,80 AQEU
IPSEN 549300M6SGDPB4Z94P11 25/09/2025 FR0010259150 1625 111,78258 CCXE
IPSEN 549300M6SGDPB4Z94P11 25/09/2025 FR0010259150 248 111,86774 TQEX
IPSEN 549300M6SGDPB4Z94P11 25/09/2025 FR0010259150 2637 112,50076 XPAR
IPSEN 549300M6SGDPB4Z94P11 26/09/2025 FR0010259150 124 110,76935 AQEU
IPSEN 549300M6SGDPB4Z94P11 26/09/2025 FR0010259150 3476 111,10964 XPAR
        22200 113,67438  

Attachment

Clinical Match Me Announces Strategic Partnership with NPACE

Posted on by

Clinical Match Me Announces Strategic Partnership with NPACE




Clinical Match Me Announces Strategic Partnership with NPACE

Clients to Benefit from Exclusive Discounts and Enhanced Educational Opportunities

San Juan, PR, Sept. 30, 2025 (GLOBE NEWSWIRE) — Clinical Match Me, a transformative force in Nurse Practitioner education, NP preceptor placement and job placement for healthcare professionals, is pleased to announce a strategic partnership with the Nurse Practitioner Associates for Continuing Education (NPACE). This collaboration marks a significant milestone in Clinical Match Me’s mission to empower Nurse Practitioner students, preceptors, and healthcare education institutions.

Clinical Match Me Announces Strategic Partnership with NPACE

Nurse Practitioner Associates for Continuing Education

Through this partnership, Clinical Match Me clients will now enjoy a 20% discount on NPACE services, enhancing their access to high-quality continuing education resources. This exclusive offer underscores Clinical Match Me’s commitment to providing comprehensive support to its clients, ensuring they have the tools and opportunities necessary to excel in their professional journeys.

NPACE, renowned for its dedication to providing evidence-based educational programs, aligns perfectly with Clinical Match Me’s vision of fostering long-lasting relationships and guiding clients through every step of their careers. By becoming an official education partner of NPACE, Clinical Match Me further solidifies its position as a leader in the healthcare education sector.

“This partnership with NPACE is a testament to our dedication to offering unparalleled resources and opportunities to our clients,” said Brad Konia, CEO of Clinical Match Me. “We are excited to provide our clients with access to NPACE’s esteemed educational services, which will undoubtedly enhance their professional development and success.”

Clinical Match Me continues to innovate and expand its offerings, providing preceptor placement, job placement for travel nurses, and now continuing education through its partnership with NPACE. This partnership is yet another step in Clinical Match Me’s ongoing efforts to support healthcare education and APP schools in shaping the future of healthcare.

By offering affordable credentialing and a unique staffing solution, Clinical Match Me grants healthcare facilities early access to a talent pool of providers while they are still in school. This allows facilities to evaluate candidates during clinical rotations and hire top talent before they graduate, giving them a competitive edge in the healthcare industry. Clinical Match Me also offers practicing healthcare providers the opportunity to become a preceptor and earn substantial honorariums (typically $1,000+ per rotation) while helping to train the next generation of providers.

APP schools benefit from Clinical Match Me’s outsourced preceptor placement, allowing them to focus on their core mission of educating the next generation of healthcare providers. The partnership with NPACE further enhances these offerings, providing students and professionals with additional resources to succeed.

For more information about Clinical Match Me and its partnership with NPACE, please visit their respective websites.

About Clinical Match Me

Clinical Match Me provides a Nurse Practitioner preceptor matching service that distinguishes itself through a personalized, technology-driven approach and student-friendly policies. Students sign up and submit placement requests for free, paying nothing until they accept a preceptor’s offer…a transparent, zero-risk process. The platform’s proprietary system instantly matches requests with preceptors, while a secondary outreach feature recruits out-of-network providers for difficult placements, maximizing successful matches. Offers are all-inclusive, covering both fees and honorarium, with flexible payment plans up to 24 months. Clinical Match Me uniquely allows students to review preceptor information, conduct interviews, and choose among multiple offers without upfront costs. A robust money-back guarantee protects students if their school rejects the preceptor or the preceptor cancels. With over a decade of industry leadership and hundreds of five-star reviews, Clinical Match Me combines affordability, automation, and personalized service for a superior student experience. 

Press inquiries

Clinical Match Me
https://www.clinicalmatchme.com
Brad Konia
brad@clinicalmatchme.com
787-356-9000
1666 Ave Ponce de Leon
San Juan, PR 00909

Sequana Medical’s alfapump® System Featured in Presentation at 2025 Portal Intervention Symposium

Posted on by

Sequana Medical’s alfapump® System Featured in Presentation at 2025 Portal Intervention Symposium




Sequana Medical’s alfapump® System Featured in Presentation at 2025 Portal Intervention Symposium

Dr. Rahul Patel of Icahn School of Medicine at Mount Sinai presented “alfapump®: Totally Implantable Peritoneal Drain Pump with Urinary Bladder Drainage”

Ghent, Belgium – September 30, 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced that the alfapump® System was featured in a podium presentation at the 2025 Portal Intervention Symposium in Chicago, IL. The presentation, titled “alfapump®: Totally Implantable Peritoneal Drain Pump with Urinary Bladder Drainage,” focused on the surgical and technical aspects of the alfapump implant procedure for interventional radiologists.

Dr. Rahul Patel, Assistant Professor of Radiology and Surgery, Icahn School of Medicine at Mount Sinai, who presented at the symposium, commented: “The alfapump system represents a significant advancement in the management of recurrent or refractory ascites due to liver cirrhosis. From an intervention perspective, the implant procedure builds on established interventional radiology techniques while providing patients with a new treatment option. The ability to continuously and automatically remove ascites from the abdomen into the bladder offers our patients freedom from the burden of repeated large volume paracentesis procedures.”

Dr. Gijs Klarenbeek, Chief Medical Officer of Sequana Medical, continued: “We are delighted to see the alfapump system featured at this important specialty conference for the interventional radiology community. This presentation will raise awareness of the alfapump amongst the interventional radiologist community and is key in ensuring they have the knowledge and confidence to offer this innovative device to their patients. For too long, many patients with recurrent or refractory ascites due to liver cirrhosis have had to put up with a standard of care that has changed little in over 2,000 years. The alfapump is a 21st century solution recognising that cirrhosis is increasingly a mainstream disease and patients are demanding and deserving better treatment options.”

The alfapump® system received U.S. FDA Premarket Approval in December 2024 for the treatment of recurrent or refractory ascites due to liver cirrhosis. It is the first active implantable medical device in the U.S. that automatically and continuously removes ascites from the abdomen into the bladder.

For more information, please contact:

Sequana Medical
Investor relations
E: IR@sequanamedical.com
T: +44 (0) 797 342 9917

Media Relations:
Jon Yu
ICR Healthcare
E: Sequana@icrhealthcare.com
T: +1 (646) 677-1855

Important Safety Information:

Indication for Use: The alfapump® System is intended for single patient use only in adult patients with refractory or recurrent ascites due to liver cirrhosis. It is indicated for the removal of excess peritoneal fluid from the peritoneal cavity into the bladder, where it can be eliminated through normal urination.

Contraindications: MRI Safety Information: The alfapump® System is MRI unsafe. This diagnostic procedure is contraindicated due to possible movement of the alfapump®, damage to the pump circuitry, tissue damage in the vicinity of the alfapump® and/or catheter dislocation. Hyperbaric oxygen therapy is contraindicated because the environmental conditions entailed in this therapy are out of the defined range of use for the alfapump® System.

Warnings, Risks, and Precautions: The implantation of the alfapump® may result in infection that could delay liver transplant or impact transplant listing status. Additional risks associated with implanting the alfapump® System including risk of peritoneal cavity infections/peritonitis, Coagulopathy, Small bladder capacity and/or obstructive uropathy.  The following procedures or therapies could impact the alfapump® System function: Supersonic therapy and high-frequency heat therapy, Transcutaneous Electrical Nerve Stimulation (TENS), Lithotripsy, Defibrillation, Radiation therapy, Electrocautery, or use of other implantable medical devices and wearable devices.

Adverse Events: In addition to procedure related risks the following Adverse Events may occur: pump pocket hematoma, skin erosion, infection, pump migration, catheter clogging or other catheter complications resulting in tissue damage or loss of or change in therapy, genito-urinary complications, reduced kidney function, hepatic encephalopathy, progression of liver disease, and other systemic effects.

Caution: the law restricts the sale by or on the order of a physician. Refer to package insert provided with the product for complete Instructions for Use, Contraindications, Potential Adverse Effects, Warnings and Precautions prior to using this product.

The alfapump® System is currently not approved in Canada.

DSR® therapy is still in development and is currently not approved in any country. The safety and effectiveness of DSR® therapy has not been established.

Note: alfapump® and DSR® are registered trademarks.

About Sequana Medical

Sequana Medical NV is a pioneer in treating fluid overload, a serious and frequent clinical complication in patients with liver disease, heart failure and cancer. This causes major medical issues including increased mortality, repeated hospitalizations, severe pain, difficulty breathing and restricted mobility. Although diuretics are standard of care, they become ineffective, intolerable or exacerbate the problem in many patients. There are limited effective treatment options, resulting in poor clinical outcomes, high costs and a major impact on their quality of life. Sequana Medical is seeking to provide innovative treatment options for this large and growing “diuretic resistant” patient population. alfapump® and DSR® are Sequana Medical’s proprietary platforms that work with the body to treat diuretic-resistant fluid overload, and are intended to deliver major clinical and quality of life benefits for patients, while reducing costs for healthcare systems.

The Company received US FDA approval for the alfapump System for the treatment of recurrent or refractory ascites due to liver cirrhosis in December 2024, following the grant of FDA Breakthrough Device Designation in 2019. In Sequana Medical’s POSEIDON study, a landmark study across 18 centers in the US and Canada, the pivotal cohort of 40 patients implanted with the alfapump showed at 6 and 24 months post-implantation the virtual elimination of therapeutic paracentesis and an improvement in quality of life1,2.

Sequana Medical has commenced US commercialisation through a small specialty salesforce initially targeting US liver transplant centers – 90 of these centers perform more than 90% of US liver transplants annually. CMS has approved the New Technology Add-on Payment for the alfapump when performed in the hospital inpatient setting as of October 1, 2025.

Results of the Company’s RED DESERT and SAHARA proof-of-concept studies in heart failure published in European Journal of Heart Failure in April 2024 support DSR’s mechanism of action as breaking the vicious cycle of cardiorenal syndrome. All three patients from the non-randomized cohort of MOJAVE, a US randomized controlled multi-center Phase 1/2a clinical study, have been successfully treated with DSR, resulting in a dramatic improvement in diuretic response and virtual elimination of loop diuretic requirements.3 The independent Data Safety Monitoring Board approved the start of the randomized MOJAVE cohort of up to a further 30 patients, which is dependent on securing additional financing.

Sequana Medical is listed on the regulated market of Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium. For further information, please visit www.sequanamedical.com.

Forward-looking statements

This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not guarantees of future performance. These forward-looking statements represent the current judgment of Sequana Medical on what the future holds, and are subject to risks and uncertainties that could cause actual results to differ materially. Sequana Medical expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release, except if specifically required to do so by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of Sequana Medical only as of the date of this press release.

1 alfapump system SSED (summary of safety and effectiveness) PMA 230044
2 as defined by subjective physical health (assessed by SF-36 PCS) and ascites symptoms (assessed by Ascites Q)
3 Data reported in press release of March 25, 2024; mean increase of 326% in six-hour urinary sodium excretion at 3 months follow up vs baseline, and 95% reduction of loop diuretics over same period

Attachments

Major Wellbeing Organization Selects Aino’s SaaS Platform

Posted on by

Major Wellbeing Organization Selects Aino’s SaaS Platform




Major Wellbeing Organization Selects Aino’s SaaS Platform

Aino Health AB (publ) has signed an agreement—facilitated through its occupational health collaboration partner Työterveys Aalto Occupational Health Care —with a leading wellbeing sector organization, covering 11,000 employees. The implementation of Aino’s SaaS platform is planned to begin within 2025, aiming to enhance proactive work ability management and employee well-being across the organization. 

“We are honored to support this organization in their mission to improve employee health and reduce work-related risks,” says Jyrki Eklund, CEO of Aino Health. “This partnership reflects the growing demand for data-driven solutions in the wellbeing industry.” 

Through the Aino platform, the organization will gain access to: 

  • Real-time health and productivity data 
  • Automated early support processes 
  • Tools for identifying root causes of health challenges 

These capabilities are designed to reduce sickness absences, improve operational efficiency, and foster a culture of proactive employee support. 

This agreement marks a significant step in Aino Health’s strategic expansion into the wellbeing sector and reinforces its position as a leading provider of health management solutions in Europe. 

For more information 
Jyrki Eklund, CEO Aino Health 
Phone: +358 40 042 4221 
Email: jyrki.eklund@ainohealth.com 

Certified Adviser 
DNB Carnegie Investment Bank AB 
More info: https://investors.ainohealth.com/certified-adviser/

About Aino Health (publ) 
Aino Health is the leading provider of Software as a Service (SaaS) solutions for Corporate Health Management. Our platform helps organizations reduce sickness absences, identify root causes of health challenges, and systematize proactive support for employees. For more information, please visit ainohealth.com.